iRadimed/$IRMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRadimed
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Ticker
$IRMD
Sector
Primary listing
Employees
160
Headquarters
Website
iRadimed Metrics
BasicAdvanced
$911M
44.48
$1.61
0.95
$0.66
0.95%
Price and volume
Market cap
$911M
Beta
0.95
52-week high
$74.43
52-week low
$46.86
Average daily volume
50K
Dividend rate
$0.66
Financial strength
Current ratio
8.778
Quick ratio
6.012
Dividend payout ratio (TTM)
39.33%
Profitability
EBITDA (TTM)
24.603
Gross margin (TTM)
76.96%
Net profit margin (TTM)
26.61%
Operating margin (TTM)
30.67%
Effective tax rate (TTM)
20.66%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
15.15%
Return on equity (TTM)
23.75%
Valuation
Price to earnings (TTM)
44.483
Price to revenue (TTM)
11.711
Price to book
9.66
Price to tangible book (TTM)
9.66
Price to free cash flow (TTM)
68.194
Free cash flow yield (TTM)
1.47%
Free cash flow per share (TTM)
1.05
Dividend yield (TTM)
0.92%
Forward dividend yield
0.95%
Growth
Revenue change (TTM)
11.73%
Earnings per share change (TTM)
10.28%
3-year revenue growth (CAGR)
17.54%
10-year revenue growth (CAGR)
13.55%
3-year earnings per share growth (CAGR)
18.85%
10-year earnings per share growth (CAGR)
17.50%
What the Analysts think about iRadimed
Analyst ratings (Buy, Hold, Sell) for iRadimed stock.
Bulls say / Bears say
Q2 2025 revenue hit a record $20.4 million, up 14% year-over-year. This marks the sixteenth straight quarter of growth and exceeded analyst expectations.
Raised full-year 2025 revenue guidance to $80.0–82.5 million (from the prior $78.0–82.0 million), highlighting management's confidence in ongoing demand.
Secured FDA 510(k) clearance for its next-generation MRidium 3870 IV Infusion Pump System, underscoring technological leadership and strengthening the product pipeline.
Anticipated remaining facility payments of approximately $1.1 million due in Q3 2025 could constrain free cash flow and limit margin expansion.
IRMD trades at a trailing P/E of about 36.3x and a forward P/E near 33.7x, making its valuation high compared to its peers, which heightens downside risk if growth slows.
The company faces concentration risk from relying on a specialized lineup of MRI-compatible devices and has key-person dependence on CEO Roger Susi, leaving it exposed to potential execution setbacks.
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
iRadimed Financial Performance
Revenues and expenses
iRadimed Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRadimed stock?
iRadimed (IRMD) has a market cap of $911M as of September 16, 2025.
What is the P/E ratio for iRadimed stock?
The price to earnings (P/E) ratio for iRadimed (IRMD) stock is 44.48 as of September 16, 2025.
Does iRadimed stock pay dividends?
Yes, the iRadimed (IRMD) stock pays dividends to shareholders. As of September 16, 2025, the dividend rate is $0.66 and the yield is 0.95%. iRadimed has a payout ratio of 39.33% on a trailing twelve-month basis.
When is the next iRadimed dividend payment date?
The next iRadimed (IRMD) dividend payment date is unconfirmed.
What is the beta indicator for iRadimed?
iRadimed (IRMD) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.